Takeda may have caught attention recently for ending work on its early-stage gene therapy R&D, but a close reading of the Japanese pharma’s latest earnings report reveals it has also culled a couple of gastrointestinal assets.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,